Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

3 Landmark Studies of Adjuvant Treatment After Surgery for Malignant Melanoma Skin Cancer

3 Landmark Studies of Adjuvant Treatment After Surgery for Malignant Melanoma Skin Cancer

The 2017 European Cancer Congress (ESMO) took place on September 8-12 in Madrid. The congress brought together 23 thousand healthcare professionals interested in cancer and presented 1500 original studies. Among the areas seeking answers to important questions were presentations on the skin cancer malignant melanoma . We share 3 important studies investigating the efficacy of protective treatment after surgery for malignant melanoma.

Malignant melanoma skin cancer has a high likelihood of recurrence. The immunotherapy called interferon constitutes our standard protective treatment after surgery. Its contribution to 10-year survival is low, at % 3, and side effects make it difficult to complete the 1-year treatment duration, leading to a search for alternative protective treatments. Although the immune-system-acting drug ipilimumab, presented at the European Cancer Congress in 2016, demonstrated success, drug-related side effects again meant that only a very small proportion of patients completed the 3-year treatment period: %13.

In malignant melanoma, %40-60 have a BRAF mutation . The BRAF gene encodes a protein with serine / threonine kinase activity involved in the intracellular mitogen-activated protein kinase signaling pathway (MAPKs). Somatic BRAF gene mutations are identified in malignant melanoma skin cancer, colorectal cancer and papillary thyroid cancer. Targeted drugs developed against this mutation have shown success in metastatic (stage 4) malignant melanoma and received FDA approval.

Studies investigating the efficacy of these targeted drugs in early-stage disease were presented at ESMO 2017. They examined the efficacy of immunotherapy drugs and targeted drugs in BRAF-mutated malignant melanoma.

Studies

1. The first study compared two different cancer immunotherapy drugs. It enrolled stage 3 and 4 patients whose tumors had all been surgically removed, totaling 906 patients. In this study, called CheckMate 238, nivolumab (brand name Opdivo) was given every two weeks, and ipilimumab (Yervoy) at 10 mg/kg every 3 weeks, for 1 year or until recurrence. Disease-free survival was %70 among those receiving nivolumab, compared with %60 with ipilimumab. Besides this significant difference between the groups, discontinuation because of side effects was much less common among patients receiving nivolumab.

You May Be Interested In:

2. In operated patients carrying a BRAF mutation and at high risk of recurrence, two different targeted drugs were evaluated in combination. This phase III trial, called COMBI-AD, tested dabrafenib plus trametinib (brand names Tafinlar and Mekinist). The study included 870 patients who had undergone surgery for stage 3 disease. After an average 3-year follow-up, disease-free survival was %58 in patients using the two drugs and %39 in those not using them. A %53 reduction in recurrence or death was observed with the combination. Treatment discontinuation because of drug side effects was %26; the most common side effects were itching, fatigue and elevated liver tests, which were manageable.

3. The third study, BRIM8, evaluated the targeted drug vemurafenib (Zelboraf) in operated BRAF-mutated malignant melanoma with a high recurrence risk. It enrolled stage 2 and 3 surgical patients, totaling 500. In subgroup analysis by stage, no contribution to disease-free survival was observed in the stage 3C group. In contrast, meaningful benefit was observed in stages 2C, 3A and 3B (%45 versus %29). Side effects are a domain in which we know this drug is reliable, but despite its efficacy in stages 2C, 3A and 3B, longer follow-up and overall survival results are needed to clarify its failure in stage 3C.

You May Be Interested In:

Although all three studies are promising for our patients, we believe long-term results are needed to determine both treatment costs and side effects.

After publication of the full articles containing all details of these studies, we will follow and share FDA and national approvals concerning the use of these drugs for protective purposes.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

3 Landmark Studies of Adjuvant Treatment After Surgery for Malignant Melanoma Skin Cancer

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy